These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35879294)

  • 21. Arecoline suppresses RANKL-induced osteoclast differentiation in vitro and attenuates LPS-induced bone loss in vivo.
    Liu FL; Chen CL; Lai CC; Lee CC; Chang DM
    Phytomedicine; 2020 Apr; 69():153195. PubMed ID: 32200293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 23-Hydroxyursolic acid from Viburnum lutescens inhibits osteoclast differentiation in vitro and lipopolysaccharide-induced bone loss in vivo by suppressing c-Fos and NF-κB signalling.
    Huong LT; Gal M; Kim O; Tran PT; Nhiem NX; Kiem PV; Minh CV; Dang NH; Lee JH
    Int Immunopharmacol; 2022 Oct; 111():109038. PubMed ID: 35932612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. WHI-131 Promotes Osteoblast Differentiation and Prevents Osteoclast Formation and Resorption in Mice.
    Cheon YH; Kim JY; Baek JM; Ahn SJ; Jun HY; Erkhembaatar M; Kim MS; Lee MS; Oh J
    J Bone Miner Res; 2016 Feb; 31(2):403-15. PubMed ID: 26255791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2E-Decene-4,6-diyn-1-ol-acetate inhibits osteoclastogenesis through mitogen-activated protein kinase-c-Fos-NFATc1 signalling pathways.
    Park YR; Su XD; Shrestha SK; Yang SY; Soh Y
    Clin Exp Pharmacol Physiol; 2022 Mar; 49(3):341-349. PubMed ID: 34729812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Downregulated fat mass and obesity-associated protein inhibits bone resorption and osteoclastogenesis by nuclear factor-kappa B inactivation.
    Zhuang J; Ning H; Wang M; Zhao W; Jing Y; Liu X; Zu J; Kong P; Wang X; Sun C; Yan J
    Cell Signal; 2021 Nov; 87():110137. PubMed ID: 34469786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Osteoporosis regulation by salubrinal through eIF2α mediated differentiation of osteoclast and osteoblast.
    He L; Lee J; Jang JH; Sakchaisri K; Hwang J; Cha-Molstad HJ; Kim KA; Ryoo IJ; Lee HG; Kim SO; Soung NK; Lee KS; Kwon YT; Erikson RL; Ahn JS; Kim BY
    Cell Signal; 2013 Feb; 25(2):552-60. PubMed ID: 23178987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low‑molecular weight fucoidan inhibits the differentiation of osteoclasts and reduces osteoporosis in ovariectomized rats.
    Jin X; Zhu L; Li X; Jia J; Zhang Y; Sun X; Ma J; Liu Z; Ma X
    Mol Med Rep; 2017 Feb; 15(2):890-898. PubMed ID: 28000877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abietic acid attenuates RANKL induced osteoclastogenesis and inflammation associated osteolysis by inhibiting the NF-KB and MAPK signaling.
    Thummuri D; Guntuku L; Challa VS; Ramavat RN; Naidu VGM
    J Cell Physiol; 2018 Jan; 234(1):443-453. PubMed ID: 29932225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coenzyme q10 regulates osteoclast and osteoblast differentiation.
    Moon HJ; Ko WK; Jung MS; Kim JH; Lee WJ; Park KS; Heo JK; Bang JB; Kwon IK
    J Food Sci; 2013 May; 78(5):H785-891. PubMed ID: 23582186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Docosahexaenoic acid signaling attenuates the proliferation and differentiation of bone marrow-derived osteoclast precursors and promotes apoptosis in mature osteoclasts.
    Kim HJ; Ohk B; Yoon HJ; Kang WY; Seong SJ; Kim SY; Yoon YR
    Cell Signal; 2017 Jan; 29():226-232. PubMed ID: 27836739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Shikonin relieves osteoporosis of ovariectomized mice by inhibiting RANKL-induced NF-κB and NFAT pathways.
    Chen Y; Xie Z; Zhang Y; Xia C; Yang M; Hu X
    Exp Cell Res; 2020 Sep; 394(1):112115. PubMed ID: 32473224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
    Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin 29 inhibits RANKL-induced osteoclastogenesis via activation of JNK and STAT, and inhibition of NF-κB and NFATc1.
    Peng Q; Luo A; Zhou Z; Xuan W; Qiu M; Wu Q; Xu L; Kong X; Zhang M; Tan W; Xue M; Wang F
    Cytokine; 2019 Jan; 113():144-154. PubMed ID: 30001863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel RANKL-targeted flavonoid glycoside prevents osteoporosis through inhibiting NFATc1 and reactive oxygen species.
    Hong G; Chen Z; Han X; Zhou L; Pang F; Wu R; Shen Y; He X; Hong Z; Li Z; He W; Wei Q
    Clin Transl Med; 2021 May; 11(5):e392. PubMed ID: 34047464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Norisoboldine suppresses osteoclast differentiation through preventing the accumulation of TRAF6-TAK1 complexes and activation of MAPKs/NF-κB/c-Fos/NFATc1 Pathways.
    Wei ZF; Tong B; Xia YF; Lu Q; Chou GX; Wang ZT; Dai Y
    PLoS One; 2013; 8(3):e59171. PubMed ID: 23536866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Yukmijihwang-Tang Suppresses Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-Induced Osteoclast Differentiation and Prevents Ovariectomy (OVX)-Mediated Bone Loss.
    Han SY; Kim YK
    Molecules; 2021 Dec; 26(24):. PubMed ID: 34946658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isofraxidin Inhibits Receptor Activator of Nuclear Factor-κB Ligand-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages Isolated from Sprague-Dawley Rats by Regulating NF-κB/NFATc1 and Akt/NFATc1 Signaling Pathways.
    Wang W; Wang B
    Cell Transplant; 2021; 30():963689721990321. PubMed ID: 33573387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos.
    He L; Lee J; Jang JH; Lee SH; Nan MH; Oh BC; Lee SG; Kim HH; Soung NK; Ahn JS; Kim BY
    Bone; 2012 Jun; 50(6):1207-13. PubMed ID: 22484180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.